Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Insulin Resistance Archives
Print | Email | Share | Comments (0)

US Sale of Generic Actos Gets FDA Nod


Aug 27, 2012

Generic Actos to Be Sold In US

The Food and Drug Administration has approved US sale of generic pioglitazone (trade name Actos) for the treatment of type 2 diabetes. Actos, originally developed and trademarked by Takeda Pharmaceuticals, works by decreasing insulin resistance in type 2 patients. The prescription drug, which belongs to the class of drugs known as thiazolidinediones (TZDs), has enjoyed great commercial success in the United States since its introduction in 1999, posting estimated sales last year of $2.7 billion.

However, pioglitazone has been linked for several years to possible increases in cardiovascular and bladder problems. The Takeda drug now comes with an FDA-mandated boxed warning about possible cardiac and bladder side effects. The generic version will carry the same warnings.

Two companies will sell the generic version. Generic manufacturer Mylan Pharmaceuticals has received FDA approval to make 15, 30, and 45 mg pioglitazone tablets. The company has been granted a six-month period of exclusivity in marketing its generic. Ranbaxy Pharmaceuticals Inc., the US subsidiary of India-based Ranbaxy, has also been licensed to sell generic pioglitazone after Mylan's exclusive marketing rights end. It, too, will manufacture 15, 30, and 45 mg tablets.

Takeda has a second Actos-based drug, Actoplus Met, that will also become available in generic form. The drug combines pioglitazone and metformin. Mylan will also sell this second drug,with the same period of exclusivity. The US affiliate of Israel-based Teva Pharmaceutical Industries Ltd. will join Mylan soon after in selling a generic form of Actoplus Met.  

 


Categories: Actoplus Met , Actos, Black Box Warning, FDA, Insulin Resistance, Metformin, Mylan Pharmaceuticals, Pioglitazone, Ranbaxy Pharmaceuticals Inc., Takeda Pharmaceuticals, thiazolidinediones (TZDs), Type 2 Diabetes



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.